Last Price$10.49NASDAQ Previous Close - Last Trade as of 4:00PM ET 8/11/22

Today's Change+0.66(6.71%)
Bid (Size)N/A (N/A)
Ask (Size)N/A (N/A)
Day Low / High$10.06 - 10.68
Volume267.7 K

View Biotechnology IndustryPeer Comparison as of 08/11/2022


MeiraGTx Holdings PLC ( NASDAQ )

Price: $10.49
Change: +0.66 (6.71%)
Volume: 267.7 K
4:00PM ET 8/11/2022

Aldeyra Therapeutics Inc ( NASDAQ )

Price: $6.99
Change: -0.75 (9.69%)
Volume: 1.5 M
4:00PM ET 8/11/2022

bluebird bio Inc ( NASDAQ )

Price: $6.31
Change: +0.38 (6.41%)
Volume: 10.00
4:00PM ET 8/11/2022

BioXcel Therapeutics Inc ( NASDAQ )

Price: $15.17
Change: +0.17 (1.13%)
Volume: 409.1 K
4:00PM ET 8/11/2022

ADMA Biologics Inc ( NASDAQ )

Price: $2.23
Change: +0.11 (5.19%)
Volume: 6.4 M
4:00PM ET 8/11/2022

Read more news Recent News

MeiraGTx's Q2 Net Loss Per Diluted Share Widens; Expects Sufficient Capital Through Q4 2024
9:32AM ET 8/11/2022 MT Newswires

MeiraGTx Holdings (MGTX) reported a Q2 net loss Thursday of $0.76 per diluted share, wider than its loss of $0.46 a year earlier. Four analysts polled by...

MeiraGTx Says it Gets $100 Million Term Loan From Perceptive Advisors; MeiraGTx Shares Rise
11:18AM ET 8/03/2022 MT Newswires

MeiraGTx Holdings (MGTX) said Wednesday it has obtained a term loan from Perceptive Advisors for up to $100 million, including $75 million upon closing....

MeiraGTx Sees Positive Data From Phase 1/2 Trial of Botaretigene Sparoparvovec for X-Linked Retinitis Pigmentosa Patients
8:11AM ET 6/28/2022 MT Newswires

MeiraGTx Holdings (MGTX) said Tuesday it has seen encouraging data from a phase 1/2 clinical study of botaretigene sparoparvovec to treat patients with...

--Chardan Lowers MeiraGTx Holdings's Price Target to $46 From $55, Maintains Buy Rating
10:47AM ET 5/13/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

View all Commentary and Analysis

MeiraGTx Holdings (MGTX) Investor Presentation - Slideshow
2:01PM ET 8/11/2022 Seeking Alpha

MeiraGTx Holdings PLC (MGTX) Reports Q2 Loss, Tops Revenue Estimates
8:45AM ET 8/11/2022 Zacks

MeiraGTx Holdings PLC (MGTX) delivered earnings and revenue surprises of -31.03% and 14.70%,...

MeiraGTx (MGTX) Investor Presentation - Slideshow
4:07PM ET 5/20/2022 Seeking Alpha

Corporate Presentation March 2022
5:53PM ET 4/29/2022 Seeking Alpha

Company Profile

Business DescriptionMeiraGTx Holdings Plc engages in the development of novel gene therapy treatments. It focuses on inherited retinal diseases, neurodegenerative diseases, and severe forms of xerostomia. It operates through the following geographical segments: United States, Ireland, Netherlands, and United Kingdom. Its pipeline includes AAV CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1 and AAV-UPF1. The company was founded on March 20, 2015 and is headquartered in New York, NY. View company web site for more details
Address430 East 29th Street
New York, New York 10016
Number of Employees68
Recent SEC Filing08/11/20228-K
President, Chief Executive Officer & DirectorAlexandria Forbes
Chief Operating & Financial OfficerRichard Giroux
Chief Medical OfficerRobert K. Zeldin
Chief Development OfficerStuart Naylor

Company Highlights

Price Open$10.13
Previous Close$10.49
52 Week Range$6.59 - 24.89
Market Capitalization$469.0 M
Shares Outstanding44.7 M
SectorHealth Technology
Next Earnings Announcement08/10/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.96
Beta vs. S&P 500N/A
Net Profit Margin-224.55%
Return on Equity-47.00%

Analyst Ratings as of 05/12/2022

Consensus RecommendationConsensus Icon
Powered by Factset